North America Respiratory Devices Market Report

North America Respiratory Devices Market Size

The North America respiratory devices market size was valued at USD 7.91 billion in 2025 and is anticipated to reach USD 8.65 billion in 2026 from USD 17.68 billion by 2034, growing at a CAGR of 9.35% during the forecast period from 2026 to 2034

The North America respiratory devices market comprises a sophisticated array of medical technologies designed to diagnose, monitor, and treat pulmonary disorders across the United States and Canada. This sector includes mechanical ventilators, nebulizers, oxygen therapy equipment, and diagnostic spirometers essential for managing acute and chronic respiratory conditions. According to the American Lung Association, over 35 million Americans currently live with some form of lung disease, creating a substantial and persistent clinical need for advanced therapeutic devices. According to the Centers for Disease Control and Prevention, chronic lower respiratory diseases remain a leading cause of death in the United States, accounting for hundreds of thousands of fatalities annually. These epidemiological realities define the operational scope of this market, which prioritizes technological innovation to improve patient survival and quality of life. Healthcare systems increasingly integrate smart respiratory devices that enable remote monitoring and data-driven clinical decision-making. Regulatory bodies like the Food and Drug Administration enforce stringent safety standards, ensuring device efficacy before commercialization. The market is further shaped by reimbursement policies from Medicare and private insurers, which dictate adoption rates for novel technologies. As air quality concerns and aging demographics evolve, the demand for precise and accessible respiratory care solutions continues to intensify across the continent.

MARKET DRIVERS

Escalating Prevalence of Chronic Obstructive Pulmonary Disease

The escalating prevalence of chronic obstructive pulmonary disease directly fuels the demand for home therapy equipment within the North America respiratory devices market. According to the American Thoracic Society, approximately 16 million adults in the United States have been diagnosed with this progressive condition, necessitating long-term oxygen therapy and noninvasive ventilation. This massive patient pool creates sustained volume sales for portable oxygen concentrators and home ventilators as treatment shifts from hospitals to residential settings. According to the National Heart, Lung, and Blood Institute, hospital readmissions for chronic obstructive pulmonary disease exacerbations cost the healthcare system billions of dollars annually, driving payers to support effective home-based management tools. Manufacturers respond by developing user-friendly devices with integrated telemetry that allow clinicians to monitor adherence and adjust settings remotely. Patients prefer lightweight and quiet systems that maintain mobility and independence during daily activities. Insurance coverage expansions for home respiratory care further accelerate procurement by reducing out-of-pocket expenses. The correlation between disease severity and device utilization ensures predictable replacement cycles for consumables and hardware. Clinical guidelines now emphasize early intervention with home therapies to slow disease progression and prevent acute episodes. This chronic care paradigm solidifies the foundational demand for respiratory devices across North America.

Rising Geriatric Population

The rising geriatric population significantly increases susceptibility to respiratory failure and ventilator dependency, thereby expanding the North America respiratory devices market. According to the U.S. Census Bureau, older adults are projected to outnumber children, reaching tens of millions of people aged 65 and above. This demographic shift correlates directly with higher incidence rates of pneumonia, acute respiratory distress syndrome, and neuromuscular weakness requiring mechanical ventilation. According to the Journal of the American Geriatrics Society, patients over 80 years old account for a major share of all intensive care unit admissions for respiratory failure. Hospitals consequently invest in advanced critical care ventilators with lung-protective algorithms tailored to fragile elderly physiology. Long-term acute care facilities also expand their inventories of weaning protocols and tracheostomy tubes to manage prolonged ventilation needs. Age-related immunosenescence makes this cohort more vulnerable to seasonal influenza and viral pneumonias, causing cyclical spikes in device demand. Palliative care integration further drives usage of comfort-focused respiratory support devices. The sheer scale of this aging demographic guarantees structural growth for respiratory technology providers independent of transient health crises. Healthcare infrastructure planning now prioritizes geriatric respiratory capacity to accommodate this inevitable trend.

MARKET RESTRAINTS

Stringent Regulatory Approval Processes

Stringent regulatory approval processes significantly delay the commercialization of innovative respiratory technologies, hindering rapid market expansion in North America. The Food and Drug Administration classifies most respiratory devices as Class II or Class III, requiring extensive premarket notification or premarket approval submissions that can span multiple years. According to the Medical Device Innovation Consortium, the average timeline for high-risk respiratory device clearance exceeds 18 months, compared to shorter durations for less invasive categories. This prolonged validation period increases development costs and discourages smaller innovators from entering the competitive landscape. Post-market surveillance requirements add ongoing financial burdens even after a successful launch. Manufacturers must navigate complex clinical trial designs to demonstrate substantial equivalence or superiority over existing predicates. Delays in regulatory feedback often force companies to repeat testing phases, extending time to revenue generation. While these safeguards protect patient safety, they inadvertently slow the diffusion of potentially life-saving advancements like adaptive ventilation modes or novel aerosol delivery systems. Competitors in regions with faster approval pathways may gain first-mover advantages globally. The uncertainty surrounding regulatory outcomes complicates investment decisions and strategic planning. Consequently, the pace of technological refreshment in the North American market lags behind scientific discovery rates.

High Out-of-Pocket Costs and Reimbursement Limitations

High out-of-pocket costs and reimbursement limitations severely restrict patient access to advanced devices within the North America respiratory devices market. According to the Kaiser Family Foundation, average annual deductibles for employer-sponsored health plans have risen notably over the past decade, forcing patients to bear significant upfront expenses for durable medical equipment. Many next-generation portable oxygen concentrators and positive airway pressure machines carry price tags exceeding insurance caps, leaving beneficiaries to cover thousands of dollars personally. According to the Government Accountability Office, inconsistent coverage determinations among Medicare Administrative Contractors create geographic disparities in device availability. Patients often opt for older, less effective models or forego therapy entirely due to financial toxicity. Private insurers frequently require prior authorization and step therapy protocols, delaying access to clinically indicated advanced devices. Manufacturers face pricing pressure as payers negotiate aggressive rebates and limit covered product lists. This economic barrier disproportionately affects low-income and rural populations who already experience higher respiratory disease burdens. Even when devices are covered, high co-payments deter adherence and long-term usage. The misalignment between technological capability and affordability stifles market penetration despite clear clinical benefits. Financial assistance programs provide only partial relief, leaving a substantial access gap unaddressed.

MARKET OPPORTUNITIES

Integration of Artificial Intelligence

The integration of artificial intelligence enables predictive analytics and personalized ventilation strategies are presenting a promising opportunity for the North America respiratory devices market. According to the American Medical Informatics Association, machine learning algorithms analyzing ventilator waveform data can predict extubation readiness with 85% accuracy, reducing unnecessary ventilation days. This capability allows manufacturers to differentiate products through intelligent software layers that optimize clinical outcomes beyond basic hardware functions. According to National Institutes of Health-funded studies, AI-driven closed-loop ventilation reduces barotrauma incidence significantly in critically ill patients. Hospitals actively seek smart devices that automate complex adjustments and reduce clinician cognitive load during staffing shortages. Data aggregation from connected devices creates valuable real-world evidence streams for research and product refinement. Payers recognize value-based purchasing potential where reimbursement ties to algorithmic performance metrics rather than mere device provision. Startups specializing in respiratory AI attract significant venture capital, signaling strong investor confidence in this convergence. Regulatory agencies are establishing frameworks for software as a medical device, accelerating approval pathways for algorithmic updates. This technological synergy transforms respiratory devices from passive tools into active clinical partners. Early adopters gain competitive advantage through superior outcomes and operational efficiency.

Expansion of Telehealth Infrastructure

The expansion of telehealth infrastructure supports remote monitoring and management of chronic respiratory conditions, which is creating substantial growth avenues for the North America respiratory devices market. According to the American Telemedicine Association, a vast majority of U.S. hospitals now offer remote patient monitoring programs integrating data from home respiratory devices into electronic health records. This digital connectivity enables proactive intervention before minor symptoms escalate into emergency department visits. According to the Centers for Medicare and Medicaid Services, permanently expanded reimbursement for remote physiologic monitoring codes incentivizes providers to prescribe connected spirometers and oximeters. Patients benefit from continuous feedback loops that reinforce medication adherence and self-management behaviors. Device manufacturers embed cellular or Bluetooth modules to ensure seamless data transmission without requiring patient technical expertise. Rural health networks leverage telehealth to extend specialist oversight to underserved communities lacking local pulmonologists. Clinical trials validate that remote management reduces hospitalizations for asthma and chronic obstructive pulmonary disease by up to 30%. Insurers view this model as a cost-containment strategy supporting broader coverage decisions. The interoperability of devices with major telehealth platforms ensures scalability across diverse health systems. This infrastructure maturity converts episodic care into continuous relationship-based management, driving recurring device and service revenue.

MARKET CHALLENGES

Persistent Supply Chain Vulnerabilities

Persistent supply chain vulnerabilities disrupt the availability of critical components and finished goods are challenging the stability of the North America respiratory devices market. According to the ResMed annual report, global semiconductor shortages delayed production volumes significantly, impacting timely fulfillment of hospital and home care orders. Just-in-time manufacturing models optimized for efficiency proved fragile during geopolitical tensions and logistics disruptions. The U.S. Department of Commerce identified medical-grade sensors and microcontrollers as high-risk items with limited domestic sourcing alternatives. Hospitals experienced stockouts of essential ventilator circuits and filters, forcing temporary rationing or substitution with inferior options. Suppliers face extended lead times for raw materials, increasing inventory carrying costs and working capital requirements. Tariffs and trade restrictions further inflate component prices, eroding manufacturer margins. Diversification efforts require significant capital investment and lengthy qualification processes for new vendors. Small and medium enterprises lack bargaining power to secure allocations during scarcity periods. Regulatory revalidation requirements for alternate suppliers add complexity and delay mitigation strategies. These system fragilities undermine confidence in reliable device access during both routine operations and public health emergencies. Strategic stockpiling provides only a temporary buffer against structural supply deficits.

Acute Shortage of Respiratory Therapists

The acute shortage of respiratory therapists limits the effective utilization of complex medical devices are further constraining market realization in North America. According to the American Association for Respiratory Care, a national deficit of 30,000 credentialed therapists is projected due to retirements and insufficient educational pipeline capacity. Without adequate skilled operators, advanced ventilators and extracorporeal membrane oxygenation systems cannot be deployed safely or optimally in clinical settings. According to the Bureau of Labor Statistics, respiratory therapist job openings have grown much faster than the average for all occupations, yet graduation rates remain stagnant. Hospitals restrict equipment purchases to match available staffing levels rather than patient acuity needs. Overtime and burnout among existing staff increase error rates and reduce protocol adherence, compromising device efficacy. Training new personnel on sophisticated technologies requires dedicated educator time, which is scarce amid clinical demands. Rural and community hospitals face disproportionate shortages, limiting access to advanced respiratory care outside academic centers. Manufacturers must simplify user interfaces and enhance automation to compensate for workforce gaps. Educational institutions struggle to expand programs due to clinical site limitations and faculty shortages. This human capital bottleneck decouples technological availability from actual patient benefit. Until workforce capacity aligns with device complexity, market growth remains artificially capped regardless of clinical need.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

The therapeutic devices segment led the market by commanding the largest share of the North America respiratory devices market in 2025. The growth of the therapeutic devices segment in this regional market is attributed to the critical need for life-sustaining interventions in acute and chronic care settings. According to the American Thoracic Society, over 1 million patients in the United States require long-term oxygen therapy or non-invasive ventilation annually, creating a massive installed base for ventilators and concentrators. This high patient volume ensures consistent procurement cycles for hospitals and home care providers alike. According to the Centers for Medicare and Medicaid Services, respiratory therapy services account for billions of dollars in annual expenditures, reflecting the heavy reliance on mechanical support for disease management. Hospitals prioritize advanced ventilators with lung-protective strategies to reduce mortality in intensive care units. The prevalence of sleep apnea further expands the market as continuous positive airway pressure machines become standard first-line treatments. Manufacturers focus on durability and ease of use to meet the demands of both clinical professionals and home users. Regulatory approvals for new therapeutic modalities, such as high-flow nasal cannula systems, have accelerated adoption in emergency departments. Insurance coverage for durable medical equipment supports patient access to these essential technologies. The segment benefits from recurring revenue streams through maintenance contracts and accessory sales. Clinical guidelines increasingly mandate early initiation of therapeutic support to prevent disease progression. This institutional and consumer demand solidifies the dominance of therapeutic devices in the regional landscape.

However, the diagnostic and monitoring devices segment is projected to register the highest CAGR of 10.5% over the forecast period in the North America respiratory devices market owing to the shift towards preventive care and remote health management. According to the American Lung Association, early detection of pulmonary function decline can reduce hospitalization rates significantly, driving demand for portable spirometers and peak flow meters. Healthcare providers are integrating these tools into routine screenings for smokers and occupational hazard exposures. According to the National Institutes of Health, wearable pulse oximeters and respiratory rate monitors enable real-time tracking of vital signs, allowing for timely clinical intervention. This capability is crucial for managing post-discharge recovery and chronic condition stability at home. Telehealth platforms rely on accurate home diagnostic data to make informed treatment decisions without physical visits. Technological advancements have miniaturized sensors, making them comfortable for continuous wear during daily activities. Patients appreciate the empowerment that comes from self-monitoring their respiratory health metrics. Insurance payers are beginning to reimburse for remote physiologic monitoring codes, encouraging broader adoption. Startups are introducing smartphone-connected devices that simplify data sharing with clinicians. The integration of artificial intelligence helps interpret complex respiratory patterns, enhancing diagnostic precision. This convergence of technology and preventive medicine drives rapid expansion in this segment.

By End User Insights

The hospitals segment led the market with the leading share of the North America respiratory devices market in 2025 due to their role as primary centers for acute respiratory failure management and critical care. According to the Society of Critical Care Medicine, intensive care units in the United States manage millions of admissions annually, with a significant portion requiring mechanical ventilation or advanced respiratory support. These facilities possess the capital resources to invest in high-end ventilators, extracorporeal membrane oxygenation systems, and sophisticated monitoring arrays. According to the American Hospital Association, respiratory care departments are among the fastest-growing clinical services due to rising acuity levels and aging patient populations. Hospitals drive innovation by adopting the latest technologies to improve survival rates and reduce length of stay. Accreditation standards mandate specific equipment ratios and capabilities, ensuring consistent demand for certified devices. Group purchasing organizations negotiate bulk contracts that streamline procurement for large health systems. Teaching hospitals serve as training grounds for new respiratory therapies, influencing future adoption patterns. The concentration of specialized pulmonologists and intensivists in hospital settings ensures optimal utilization of complex devices. Emergency preparedness initiatives further boost inventory levels of critical respiratory equipment. This centralization of expertise and infrastructure makes hospitals the dominant force in device consumption.

On the other end, the homecare segment is anticipated to showcase a promising CAGR in the North American market over the forecast period owing to the strategic shift towards decentralized care models and patient preference for comfort. According to the Centers for Medicare and Medicaid Services, home health services have expanded notably in recent years as policies encourage treating patients in less restrictive environments. Chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease are increasingly managed at home using portable nebulizers and oxygen concentrators. According to the Journal of Pulmonary and Respiratory Medicine, home-based respiratory care reduces readmission rates significantly compared to traditional outpatient follow-up alone. Patients benefit from reduced exposure to hospital-acquired infections and greater autonomy in their daily routines. Advances in battery technology have made respiratory devices lighter and more portable, facilitating active lifestyles. Family caregivers receive training on device operation, enhancing adherence and safety. Private insurers are expanding coverage for home durable medical equipment to lower overall healthcare costs. Direct-to-consumer marketing by manufacturers raises awareness of available home solutions. Telehealth integration allows clinicians to monitor home device usage remotely, adjusting therapies as needed. The aging population prefers aging in place, which drives demand for reliable home respiratory support. This trend transforms the home into a primary site for respiratory care delivery.

COUNTRY ANALYSIS

The U.S. dominated the market by holding the highest share of the North American market in 2025 and is projected to maintain its strong market leadership through sustained healthcare spending and high innovation capacity over the next few years. The United States holds the dominant position in the North America Respiratory Devices Market, supported by advanced healthcare infrastructure and high prevalence of respiratory diseases. According to the Centers for Disease Control and Prevention, chronic lower respiratory diseases affect millions of Americans, creating a sustained demand for therapeutic and diagnostic solutions. The presence of major global manufacturers and innovative startups fosters a competitive environment that accelerates technological advancement. The Food and Drug Administration maintains rigorous approval standards, ensuring high quality and safety for medical devices. Medicare reimbursement policies significantly influence adoption rates for home respiratory equipment and remote monitoring services. The country leads in clinical research and trials for novel respiratory therapies, attracting significant investment. High healthcare expenditure per capita enables access to premium devices and personalized care plans. Public health initiatives focusing on smoking cessation and air quality improvement aim to reduce disease burden, but current prevalence remains high. The integration of electronic health records facilitates seamless data exchange between home devices and hospital systems. Academic medical centers drive education and best practice dissemination for respiratory care professionals. The robust private insurance market complements public coverage, ensuring broad access to necessary technologies. This ecosystem supports continuous innovation and widespread deployment of respiratory devices across diverse care settings.

Canada is anticipated to experience steady expansion driven by ongoing public health initiatives and increasing utilization of digital healthcare solutions over the next few years. Canada maintains a significant position in the North America respiratory devices market, characterized by its universal healthcare system and focus on equitable access. According to the Canadian Lung Association, respiratory diseases rank among the leading causes of death in the country, necessitating comprehensive management strategies. Provincial health plans cover essential respiratory devices, ensuring that financial barriers do not prevent patients from receiving necessary care. According to the Canadian Agency for Drugs and Technologies in Health, systematic evaluations of new respiratory technologies guide cost-effective procurement decisions. Rural and remote communities benefit from telehealth initiatives that connect patients with specialists in urban centers. The government invests in public health campaigns to address smoking and environmental pollutants affecting lung health. Local distributors partner with international manufacturers to ensure supply chain reliability across vast geographic areas. Clinical guidelines developed by Canadian thoracic societies standardize care practices nationwide. Research institutions collaborate on studies related to indigenous health disparities in respiratory outcomes. The aging population drives demand for home care services and portable respiratory equipment. Regulatory harmonization with international standards facilitates the entry of innovative devices. The emphasis on preventive care and early intervention supports the growth of diagnostic monitoring tools. This structured approach ensures consistent quality and accessibility of respiratory care services.

COMPETITIVE LANDSCAPE

The competition in the North America Respiratory Devices Market is characterized by a mix of global multinational corporations and specialized niche players striving for dominance. Global players leverage their extensive research capabilities and brand reputation to introduce innovative products such as smart ventilators and connected sleep therapy devices. These companies benefit from established distribution networks and strong relationships with key healthcare institutions across the region. Specialized manufacturers compete primarily on technological differentiation and clinical evidence offering unique solutions for complex respiratory conditions. The market sees intense rivalry in the home care segment where ease of use and patient comfort are crucial for maintaining competitive advantage. Companies frequently engage in strategic collaborations with government bodies and non governmental organizations to enhance their market presence and contribute to public health initiatives. Regulatory hurdles are stringent but clear creating barriers to entry for smaller firms but opportunities for those with robust compliance frameworks. The rise of value based care has intensified competition for products that demonstrate cost effectiveness and improved patient outcomes. Intellectual property protection remains a critical factor influencing competitive dynamics as firms seek to safeguard their innovations. Continuous investment in clinical evidence generation helps companies demonstrate superior efficacy and justify premium pricing. The competitive landscape is further shaped by mergers and acquisitions as larger entities seek to consolidate their position and expand their product portfolios. This dynamic environment drives continuous improvement in product quality and patient care standards throughout the North America region.

KEY MARKET PLAYERS

Companies playing a dominant role in the North America Respiratory Devices Market include

• Masimo Corporation
• ResMed, Inc.
• Fisher & Paykel Healthcare Limited
• Philips Healthcare
• Covidien plc
• CareFusion Corporation

Top Players in the North America Respiratory Devices Market

ResMed Inc

ResMed Inc maintains a dominant presence in the North America Respiratory Devices Market through its comprehensive portfolio of sleep and respiratory care solutions. The company focuses on connected health by integrating cloud based software with positive airway pressure devices to enhance patient adherence. Recent initiatives include expanding its digital health ecosystem to support remote patient monitoring for chronic obstructive pulmonary disease management. ResMed collaborates with healthcare providers to offer data driven insights that improve clinical outcomes and reduce hospital readmissions. The company invests heavily in research to develop quieter and more comfortable masks for home users. Strategic partnerships with telehealth platforms enable seamless integration of device data into electronic health records. ResMed continues to launch innovative humidification technologies that improve therapy tolerance. Their commitment to user centric design drives high patient satisfaction and brand loyalty. These efforts strengthen their reputation as a leader in home respiratory care across the region.

Philips

Philips contributes significantly to the North America Respiratory Devices Market with its advanced ventilators and noninvasive respiratory support systems. The company emphasizes critical care innovation by developing intelligent ventilation modes that adapt to patient breathing patterns in real time. Recent actions include launching next generation intensive care unit ventilators with enhanced safety features and intuitive interfaces. Philips partners with academic medical centers to conduct clinical trials validating the efficacy of its respiratory algorithms. The company actively participates in public health initiatives to improve access to respiratory care in underserved communities. They engage in training programs for respiratory therapists to maximize the utility of complex devices. Innovation in portable oxygen concentrators supports the growing demand for mobile home care solutions. Philips focuses on interoperability ensuring its devices integrate seamlessly with hospital information systems. Their holistic approach addresses both acute and chronic respiratory needs effectively. These strategies reinforce their position as a key provider of hospital grade respiratory technologies.

Fisher & Paykel Healthcare

Fisher & Paykel Healthcare plays a vital role in the North America Respiratory Devices Market by specializing in high flow nasal cannula therapy and sleep apnea solutions. The company focuses on improving patient comfort and clinical outcomes through its proprietary heated humidification technology. Recent developments include expanding its critical care product line to support neonatal and pediatric respiratory needs. Fisher & Paykel collaborates with hospitals to implement standardized protocols for high flow therapy usage. They have established strong distribution networks in the United States and Canada to ensure widespread product availability. The company invests in clinical education to promote evidence based practices among healthcare professionals. Innovation in mask design reduces skin irritation and improves seal integrity for long term users. Fisher & Paykel supports research into the benefits of humidified high flow oxygen in preventing respiratory failure. Their commitment to quality and reliability builds trust among clinicians and patients alike. These efforts help patients achieve better therapeutic results and enhanced quality of life.

Top Strategies Used by Key Market Participants

Key players in the North America Respiratory Devices Market employ several strategic approaches to strengthen their competitive position and drive growth. Product innovation remains a primary strategy as companies invest heavily in research and development to create smarter and more user friendly devices. These innovations address specific clinical needs such as improved comfort reduced noise and enhanced data connectivity. Strategic partnerships with telehealth providers enable companies to offer integrated remote monitoring solutions that improve patient adherence. Collaborations with academic institutions facilitate clinical trials and validation of new therapies ensuring regulatory approval and market acceptance. Companies also focus on educational initiatives to train healthcare professionals on proper device usage and maintenance protocols. Digital health integration is another major strategy with firms developing cloud based platforms for real time data analysis. Regulatory compliance and obtaining approvals from agencies like the FDA allow faster market entry for new products. Pricing strategies are adapted to suit different insurance segments ensuring affordability while maintaining premium positioning. Sustainability initiatives are increasingly adopted to meet environmental standards and consumer expectations. These combined strategies help companies navigate the complex regulatory and economic landscape of the North American region effectively.

RECENT MARKET DEVELOPMENTS

• In March 2024, ResMed Inc launched a new cloud based monitoring platform for sleep apnea patients. This launch is anticipated to allow ResMed Inc to enhance remote patient engagement and strengthen the North America Respiratory Devices Market
• In May 2024, Philips introduced a next generation intensive care ventilator with AI driven algorithms. This introduction is anticipated to allow Philips to improve clinical decision support and strengthen the North America Respiratory Devices Market
• In February 2024, Fisher & Paykel Healthcare expanded its distribution network in rural Canada. This expansion is anticipated to allow Fisher & Paykel Healthcare to increase product accessibility and strengthen the North America Respiratory Devices Market
• In June 2024, Medtronic partnered with a leading telehealth provider to integrate respiratory data. This partnership is anticipated to allow Medtronic to offer comprehensive remote care solutions and strengthen the North America Respiratory Devices Market
• In January 2024, Vyaire Medical acquired a startup specializing in portable oxygen concentrators. This acquisition is anticipated to allow Vyaire Medical to diversify its home care portfolio and strengthen the North America Respiratory Devices Market

MARKET SEGMENTATION

This research report on the North America Respiratory Devices Market has been segmented and sub-segmented into the following categories.

By Type 

• Therapeutic Devices
• Diagnostic & Monitoring Devices
• Disposables

By End User 

• Hospitals
• Homecare

By Country 

• US
• Canada